-
1 month ago | 
pulmonaryfibrosisnews.com | Patricia Inacio |Charlene Marshall |Andrea Lobo |Steve Bryson
Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating its idiopathic pulmonary fibrosis (IPF) treatment bexotegrast due to safety issues. The BEACON-IPF (NCT06097260) trial was assessing whether once-daily doses of bexotegrast (160 mg or 320 mg) could improve lung function in about 360 IPF patients, ages 40 and older, when compared with a placebo.
-
1 month ago | 
pulmonaryfibrosisnews.com | Marisa Wexler |Charlene Marshall |Andrea Lobo
Enrollment is now complete in a Phase 2b clinical trial, dubbed CORAL, that’s testing nalbuphine extended-release (ER) tablets — planned to be marketed as Haduvio — in people with idiopathic pulmonary fibrosis (IPF) who experience chronic cough. That achievement was announced by Trevi Therapeutics, the U.S. company developing the therapy and sponsoring the study.
-
1 month ago | 
pulmonaryfibrosisnews.com | Samuel Kirton |Marisa Wexler |Charlene Marshall
Fraternal organizations have long been a part of colleges and universities. It’s not uncommon to find an area around campus labeled as Greek Row. These organizations allow like-minded individuals to join together, taking hold even beyond college campuses. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in early 2017, I had no idea I was joining a fraternity — one that no one wants to be a part of.
-
2 months ago | 
pulmonaryfibrosisnews.com | Marisa Wexler |Charlene Marshall |Patricia Inacio |Lindsey Shapiro
A protein called Runx2 contributes to the abnormal activity of lung cells that drive pulmonary fibrosis, a new study shows, suggesting that inhibiting this protein may be an effective strategy for treating the disease.
-
2 months ago | 
pulmonaryfibrosisnews.com | Samuel Kirton |Steve Bryson |Ann Reynoso |Charlene Marshall
Have you seen the T-shirt or sign that reads “Keep Calm and Carry On” (KCCO)? You might be surprised to learn the story behind this phrase. Created in 1939, it was part of a three-poster series intended to boost morale during World War II. Ironically, the Keep Calm and Carry On poster was never published or made public. It might have faded away were it not discovered in a box at a book auction in 2000.
-
2 months ago | 
pulmonaryfibrosisnews.com | Samuel Kirton |Steve Bryson |Charlene Marshall
We’re not all the same. When I share details about my journey with idiopathic pulmonary fibrosis (IPF), I don’t want to give the impression that I’m setting a standard. My goal in writing this column is to share my experiences, which may or may not be similar to others. When Steven Nathan, MD, diagnosed me with IPF in January 2017, it was the culmination of a process that began during my annual physical in October 2016.
-
Jan 14, 2025 | 
pulmonaryfibrosisnews.com | Samuel Kirton |Charlene Marshall
Rapidly spreading wildfires have taken over the news headlines from the Los Angeles area, as I write this column. Dry weather and the Santa Ana winds joined forces to create an inferno there. Wildfires are just one emergency that the pulmonary fibrosis (PF) community must be prepared to handle. Extended power outages, hurricanes, tornadoes, earthquakes, and more can present life-threatening challenges for our community.
-
Jan 9, 2025 | 
pulmonaryfibrosisnews.com | Charlene Marshall |Steve Bryson |Samuel Kirton
Each new year brings an influx of marketing about resolutions, hopes, and wishes. If you’re like me, your social media feed is flooded with related ad campaigns this month. A new year often sparks hope for positive changes regarding a person’s physical health, mental wellness, or finances. I don’t typically fall prey to New Year’s gimmicks or set grandiose resolutions, but I do enjoy thinking about the upcoming year and my wishes for myself and those I care about.
-
Jan 7, 2025 | 
pulmonaryfibrosisnews.com | Samuel Kirton |Ann Reynoso |Charlene Marshall
Do you make resolutions for the new year? A revealing joke on the subject has been around for years. In it, an entrepreneur opens and stocks a gym on New Year’s Day to support those who’ve made resolutions to exercise. After the first two weeks, though, the gym equipment is removed, and the venture becomes a full-service bar. Even the best intentions can go awry.
-
Dec 6, 2024 | 
pulmonaryfibrosisnews.com | Lindsey Shapiro |Esteban Cerezo |Margarida Maia |Charlene Marshall
The first patient has been dosed in a Phase 2b clinical trial of Endeavor Biomedicines’ investigational oral therapy ENV-101 (taladegib) in people with idiopathic pulmonary fibrosis (IPF). WHISTLE-PF (NCT06422884) seeks to enroll around 200 adults in 14 countries. The first patient was dosed in Australia. The study’s launch was backed by positive data from a Phase 2a trial (NCT04968574) that found ENV-101 could improve lung function and ease lung scarring in adults with IPF.
